CSL Limited shares could be a great buy today

I believe the critical products that CSL Limited (ASX:CSL) manufactures should help it navigate safely through any potentially challenging economic periods.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Global specialty biotherapeutics company CSL Limited (ASX: CSL) is one of the best companies on the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) for a long-term investment in my opinion.

Thanks to its market-leading position and high levels of innovation, CSL has managed to grow its bottom line by a compound annual growth rate of almost 22% in the last 10 years.

As you would imagine, those holding its shares during this time have been thoroughly rewarded.

Those that invested $50,000 in CSL back in 2006 would have seen their investment grow to be worth approximately $370,000 today due to its average annual total shareholder return of 22.1% in the last 10 years.

So far this year things are looking just as promising for the company and its shareholders. Its interim results revealed that sales increased by 9% to US$2,996 million and earnings before interest and tax increased by 8% to US$952 million for the half year.

During the period the company successfully closed its acquisition of the Norvartis influenza vaccines business. CSL has combined it with its bioCSL business to form a new subsidiary by the name of Seqirus. In doing so it created the world's second-largest influenza vaccines developer and producer.

Although it is a loss-making business at present, CSL's management has stated that it expects it to become profitable within the next five years. I'm very optimistic about its future and believe it will be a big contributor to its growth in the years ahead.

The World Health Organization estimates that between 5% to 10% of adults and 20% to 30% of children globally are subjected to influenza related illnesses each year. In dollar terms CSL believes this to be worth around $6 billion in sales per year.

One thing that I especially like with CSL is that because its products are critical for patients suffering from haemophilia or liver deficiencies demand should remain strong. I think this could make it a great investment through the potentially volatile next few months.

Fellow biotech company Mesoblast limited (ASX: MSB) may look cheap at the moment after the huge sell off that knocked its share price down by 75% in the last 12 months. But I would still pick CSL over it every time and believe that investors will be rewarded for doing so.

CSL's shares may be changing hands at 28x trailing earnings, but for such a high quality and growing company I believe they are more than worth paying a premium for.

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »